A randomised, double-blind, placebo-controlled, dose ascending, five-way crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of a single administration of three inhaled doses (25, 100 and 400 microg) of GW642444M.

Trial Profile

A randomised, double-blind, placebo-controlled, dose ascending, five-way crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of a single administration of three inhaled doses (25, 100 and 400 microg) of GW642444M.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Vilanterol (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Jul 2010 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
    • 12 Oct 2008 Trial phase changed from I to II as reported by ClinicalTrials.gov
    • 10 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top